thumbnail image
broken image
broken image
broken image
  • Home
  • About us 
    • Management
    • Living Innovation
    • Company presentation
  • Science 
    • Pipeline
    • xLink MAb platform
    • TROY-Ig TCE platform
    • Publications
  • Patient 
    • Cancer Immunotherapy
    • LVGN6051
    • LVGN7409
    • LVGN3616
    • Resources
  • News 
    • News
    • Company presentation
  • Partners 
    • Careers
    • Collaboration
    • Contact us
  • …  
    • Home
    • About us 
      • Management
      • Living Innovation
      • Company presentation
    • Science 
      • Pipeline
      • xLink MAb platform
      • TROY-Ig TCE platform
      • Publications
    • Patient 
      • Cancer Immunotherapy
      • LVGN6051
      • LVGN7409
      • LVGN3616
      • Resources
    • News 
      • News
      • Company presentation
    • Partners 
      • Careers
      • Collaboration
      • Contact us
broken image
broken image
broken image
  • Home
  • About us 
    • Management
    • Living Innovation
    • Company presentation
  • Science 
    • Pipeline
    • xLink MAb platform
    • TROY-Ig TCE platform
    • Publications
  • Patient 
    • Cancer Immunotherapy
    • LVGN6051
    • LVGN7409
    • LVGN3616
    • Resources
  • News 
    • News
    • Company presentation
  • Partners 
    • Careers
    • Collaboration
    • Contact us
  • …  
    • Home
    • About us 
      • Management
      • Living Innovation
      • Company presentation
    • Science 
      • Pipeline
      • xLink MAb platform
      • TROY-Ig TCE platform
      • Publications
    • Patient 
      • Cancer Immunotherapy
      • LVGN6051
      • LVGN7409
      • LVGN3616
      • Resources
    • News 
      • News
      • Company presentation
    • Partners 
      • Careers
      • Collaboration
      • Contact us
broken image
  • xLinkMAb

    Monoclonal agonist antibody discovery platform

  • Lyvgen’s proprietary xLinkMAb functional platform generated agonistic monoclonal antibodies with tumor-localized immunostimulatory activities by balancing multiple functions of candidate antibodies, which has generated several drug candidates, including LVGN7409 (CD40 agonist mAb) and LVGN6051  (4-1BB agonist mAb), presently in clinical development. To increase selectivity for tumors, xLinkAb™ platform creates agonist IgG antibodies that agonize their targets optimally in the presence of FcγRIIb (FCGR2B; CD32B), which is expressed on immune cells enriched in the tumor microenvironment, including B cells, monocytes, and NK cells. A series of Lyvgen's IP protected Fc variants have been designed to achieve selective FcγRIIb binding capacity.

    broken image

    •Nature IgG structure

    •Low-affinity and high-avidity binding to FcγRIIB

    •High-affinity/specificity binding to TNFRSFs (e.g. CD137, CD40, GITR, OX40)

    •FcγRIIB-dependent TNFRSF agonism

    •No binding to other activating FcγRs

    •No ADCC/ADCP

    •IP protected multiple Fc-engineering variants

    Lyvgen Biopharma engaged in development of innovative cancer treatment, is open to collaborate or out-license our pipelines or platform technology. Please contact us to explore collaboration opportunities.

    Contact us
沪公网安备 31011502015346号
|
沪ICP备20018873号-2
    Home
    About us
    xLinkAb
    Contact us
Lyvgen Biopharma Website 礼进生物 英文官网
Lyvgen is a biotech company focused on developing novel therapies for cancer. Lyvgen’s xLinkAb™ functional platform creates agonist antibodies (Abs) with tumor-localized immunostimulatory activities by balancing multiple functions of candidate Abs.
https://user-assets.sxlcdn.com/images/676507/FiTA8WK-FQRyXrQDyd-HDkY3tpfI.png?imageMogr2/strip/auto-orient/thumbnail/1200x630>/format/png
Cookie的使用
我们使用cookies来确保流畅的浏览体验。若继续,我们认为你接受使用cookies。
了解更多